Illumina’s accelerator has an impressive 93 percent follow-on funding rate — here’re its latest picks

Since its launch in 1998, Illumina and its genetic analysis toolkits and services have become an essential component of the new biological manufacturing and therapeutic development industries that have emerged in the last 25 years. And for the past six years the company has attempted to encourage the development of the industry through an incubator … Continue reading Illumina’s accelerator has an impressive 93 percent follow-on funding rate — here’re its latest picks